Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3

查看全文 作　　者：Fang-Ming Gu, Quan-Lin Li, Qiang Gao, Jia-Hao Jiang, Xiao-Yong Huang, Jin-Feng Pan, Jia Fan, Jian ZhouFang-Ming Gu, Quan-Lin Li, Qiang Gao, Jia-Hao Jiang, Xiao-Yong Huang, Jin-Feng Pan, Jia Fan, Jian Zhou, Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Shanghai 200032, China Author contributions: Gu FM, Li QL and Gao Q contributed equally to this work;Gu FM and Li QL performed the experi- ments and interpretation of the data and statistical analysis;Zhou J and Gao Q contributed to the conception and design of the study;Gu FM, Gao Q, Li QL and Zhou J wrote the manuscript;Jiang JH, Huang XY, Pan JF and Fan J made substantial contri- bution to the design and conception of the study and interpreta- tion of data;all authors read and approved the f inal manuscript.

出　　处：《World Journal of Gastroenterology》索引2011年第17卷第34期,共11页

基　　金：Supported by Grants from the China 863 Project, No. 2007A-A02Z479;the National Natural Science Foundation of China, No. 30972949 and 30901432;Shanghai Rising-Star Program, No. 10QA1401300;Research Fund for the Doctoral Program of Higher Education of China, No. 20090071120026 摘　　要：AIM: To investigate the inhibitory role and the underlying mechanisms of sorafenib on signal transducer and activator of transcription 3 (STAT3) activity in hepatocellular carcinoma (HCC).METHODS: Human and rat HCC cell lines were treated with sorafenib. Proliferation and STAT3 dephosphorylation were assessed. Potential molecular mechanisms of STAT3 pathway inhibition by sorafenib were evaluated. In vivo antitumor action and STAT3 inhibition were investigated in an immunocompetent orthotopic rat HCC model.RESULTS: Sorafenib decreased STAT3 phosphorylationat the tyrosine and serine residues (Y705 and S727), but did not affect Janus kinase 2 (JAK2) and phosphatase shatterproof 2 (SHP2), which is associated with growth inhibition in HCC cells. Dephosphorylation of S727 was associated with attenuated extracellular signal-regulated kinase (ERK) phosphorylation, similar to the effects of a mitogen-activated protein kinase (MEK) inhibitor U0126, suggesting that sorafenib induced S727 dephosphorylation by inhibiting MEK/ERK signaling. Meanwhile, sorafenib could also inhibit Akt phosphorylation, and both the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and Akt knockdown resulted in Y705 dephosphorylation, indicating that Y705 dephosphorylation by sorafenib was mediated by inhibiting the PI3K/Akt pathway. Finally, in the rat HCC model, sorafenib signifi cantly inhibited STAT3 activity, reducing tumor growth and metastasis.CONCLUSION: Sorafenib inhibits growth and metastasis of HCC in part by blocking the MEK/ERK/STAT3 and PI3K/Akt/STAT3 signaling pathways, but independent of JAK2 and SHP2 activation. 关键词：STAT3 细胞生长肝癌 JANUS激酶细胞外信号调节激酶去磷酸化磷脂酰肌醇-3 信号转导

相关文献

参考文献（31）
引证文献（19）
耦合文献（0）

参考文献(31)

引证文献(19)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3

参考文献(31)

引证文献(19)

用户提示